Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 combinations versus capecitabine in advanced pancreatic cancer
ChiCTR1900024095Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, Rivoceranib and capecitabine in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Shanghai General Hospital. Primary endpoint: Overall survival. Started Jan 2018; status: recruiting.
02
Drugs
camrelizumabRivoceranibcapecitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1900024095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024095.